Phaseline

Companies › Bavarian Nordic

Bavarian Nordic: clinical trials, targets and expected readouts

2 active drug programs in 7 registered trials: 4 Phase 2, 3 Phase 3; Infectious disease, Neurology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CHIKV VLP vaccine booster (PXVX0317, VIMKUNYA®)
Chikungunya virus-like particles (CHIKV VLP) vaccine with aluminum hydroxide adjuvant
–Phase 3Chikungunya Virus Infection; Chikungunya VirusFeb 2028
MVA-BN (CEF)
Live attenuated vaccinia virus expressing mpox antigens
–Phase 2Monkeypox (Mpox); EncephalitisNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06549530MVA-BN (CEF)Phase 2Monkeypox (Mpox)Infectious diseaseMay 2026
NCT07199569MVA-BN (CEF)Phase 2Monkeypox (Mpox)Infectious diseaseNov 2026
NCT07199569MVA-BN (CEF)Phase 2Monkeypox (Mpox)Infectious diseaseNov 2026
NCT06899802MVA-BN (CEF)Phase 2EncephalitisNeurologyFeb 2027
NCT06007183CHIKV VLP vaccine booster (PXVX0317, VIMKUNYA®)Phase 3Chikungunya Virus InfectionInfectious diseaseFeb 2028
NCT07003984CHIKV VLP vaccine booster (PXVX0317, VIMKUNYA®)Phase 3Chikungunya VirusInfectious diseaseSep 2028
NCT07467707CHIKV VLP vaccine booster (PXVX0317, VIMKUNYA®)Phase 3Chikungunya VirusInfectious diseaseMay 2030

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Sinovac Life Sciences Bharat Biotech International MAXVAX Biotechnology Limited Liability Company Aimei Vacin BioPharm (Zhejiang) Changchun BCHT Biotechnology

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.